Small-cell lung cancer (SCLC) represents approximately 15% of lung cancer cases and has a poor prognosis; about two-thirds of patients present at an extensive-stage (ES) disease state, and the 5-year overall survival (OS) rate is limited to only 1–5% (refs.1,2). The addition of an...
HORN L,Zhao Z,Sandler A,et al.A Phase II study of carboplatinand irinotecan in extensive stage small-cell lung cancer. ClinLung Cancer . 2011HORN L,Zhao Z,Sandler A,et al. A Phase Ⅱ study of carbo- platin and irinotecan in extensive stage small cell lung cancer [J]. Clin Lung ...
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Small Cell Lung Cancer View LargeDownload Figure 1. Recruitment, Randomization, and Flow of Patients With Extensive-Stage Small Cell Lung Cancer in the ASTRUM-005 Trial View LargeDownload The date of ...
Abstract CT216: Response to first-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) in non-small cell lung cancer (NSCLC) by blood tumor mutational b... Background: 1L pembro + platinum-based chemo has shown clinical activity in metastatic NSCLC regardless of tissue tumor mutational ...
Research teams have conducted studies that show beyond all reasonable doubt that tobacco smoking is associated with a shortened life expectancy. Cigarette smoking is believed by most research workers, in this field to be an important factor in the development of cancer of the lungs and cancer of ...